I agree with Bear that the following is germane to SP considerations in the near term:

"IR replied "It would be our intention to announce when we reach 250+ narrow events which will likely include info relating to end of dosing. Yes we plan to announce when we reach 250+ narrow events.""

Things could become quite interesting if RVX also released the accumulated number of patients-years in the study at the point at which those 250 narrow MACE events occurred.  This would allow an inference to be made about the likelihood that apabetalone had influenced (increased in particular) the time to MACE by comparison with the expected placebo MACE rate (a subject that has already generated plenty of discussion on the board - you can choose your own expected rate for the placebo arm). 

Jupe